Association of vitamin D deficiency with COVID-19 severity and mortality in Iranian people: a prospective observational study
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background As the coronavirus disease 2019 (COVID-19) pandemic continues to escalate, it is important to identify the prognostic factors related to increased mortality and disease severity. To assess the possible associations of vitamin D level with disease severity and survival, we studied 248 hospitalized COVID-19 patients in a single center in a prospective observational study from October 2020 to May 2021 in Tehran, Iran. Methods Patients who had a record of their 25-hydroxyvitamin D level measured in the previous year before testing positive with COVID-19 were included. Serum 25-hydroxyvitamin D level was measured upon admission in COVID-19 patients. The associations between clinical outcomes of patients and 25-hydroxyvitamin D level were assessed by adjusting for potential confounders and estimating a multivariate logistic regression model. Results The median (interquartile range) age of patients was 60 years (44–74 years), and 53% were male. The median serum 25-hydroxyvitamin D level prior to admission decreased with increasing COVID-19 severity (P=0.009). Similar findings were obtained when comparing median serum 25-hydroxyvitamin D on admission between moderate and severe patients (P=0.014). A univariate logistic regression model showed that vitamin D deficiency prior to COVID-19 was associated with a significant increase in the odds of mortality (odds ratio, 2.01; P=0.041). The multivariate Cox model showed that vitamin D deficiency on admission was associated with a significant increase in risk for mortality (hazard ratio, 2.35; P=0.019). Conclusions: Based on our results, it is likely that deficient vitamin D status is associated with increased mortality in COVID-19 patients. Thus, evaluating vitamin D level in COVID-19 patients is warranted.
Abstract
Background As the coronavirus disease 2019 (COVID-19) pandemic continues to escalate, it is important to identify the prognostic factors related to increased mortality and disease severity. To assess the possible associations of vitamin D level with disease severity and survival, we studied 248 hospitalized COVID-19 patients in a single center in a prospective observational study from October 2020 to May 2021 in Tehran, Iran. Methods Patients who had a record of their 25-hydroxyvitamin D level measured in the previous year before testing positive with COVID-19 were included. Serum 25-hydroxyvitamin D level was measured upon admission in COVID-19 patients. The associations between clinical outcomes of patients and 25-hydroxyvitamin D level were assessed by adjusting for potential confounders and estimating a multivariate logistic regression model. Results The median (interquartile range) age of patients was 60 years (44–74 years), and 53% were male. The median serum 25-hydroxyvitamin D level prior to admission decreased with increasing COVID-19 severity (P=0.009). Similar findings were obtained when comparing median serum 25-hydroxyvitamin D on admission between moderate and severe patients (P=0.014). A univariate logistic regression model showed that vitamin D deficiency prior to COVID-19 was associated with a significant increase in the odds of mortality (odds ratio, 2.01; P=0.041). The multivariate Cox model showed that vitamin D deficiency on admission was associated with a significant increase in risk for mortality (hazard ratio, 2.35; P=0.019). Conclusions: Based on our results, it is likely that deficient vitamin D status is associated with increased mortality in COVID-19 patients. Thus, evaluating vitamin D level in COVID-19 patients is warranted.
참고문헌 (25)
- "COVID-19 corona virus pandemic" (2021)[URL]
- Weiss P, "Clinical course and mortality risk of severe COVID-19", Lancet, 395, pp.1014~1015 (2020)
- Holick MF, "The vitamin D deficiency pandemic: approaches for diagnosis, treatment and prevention", Rev Endocr Metab Disord, 18, pp.153~165 (2017)
- Charoenngam N, "Immunologic effects of vitamin D on human health and disease", Nutrients, 12, pp.2097~ (2020)
- Zdrenghea MT, "Vitamin D modulation of innate immune responses to respiratory viral infections", Rev Med Virol, 27, pp.e1909~ (2017)
- "J Nutr", 2021, 98~103
- Aslan MT, "Letter to the editor: is vitamin d one of the key elements in COVID-19 days?", J Nutr Health Aging, 24, pp.1038~1039 (2020)
- Herr C, "The role of cathelicidin and defensins in pulmonary inflammatory diseases", Expert Opin Biol Ther, 7, pp.1449~1461 (2007)
- Agier J, "Cathelicidin impact on inflammatory cells", Cent Eur J Immunol, 40, pp.225~235 (2015)
- Yisak H, "Effects of vitamin D on COVID-19 infection and prognosis : a systematic review", Risk Manag Healthc Policy, 14, pp.31~38 (2021)
- Liu N, "Low vitamin D status is associated with coronavirus disease 2019 outcomes : a systematic review and meta-analysis", Int J Infect Dis, 104, pp.58~64 (2021)
- Marcos Pereira, "Vitamin D deficiency aggravates COVID-19: systematic review and meta-analysis", Critical Reviews in Food Science and Nutrition, pp.1~9 (2020), Informa UK Limited[DOI]
- (2020)[URL]
- Holick MF, "Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline", J Clin Endocrinol Metab, 96, pp.1911~1930 (2011)
- Bhatraju PK, "COVID-19 in critically ill patients in the Seattle Region : case series", N Engl J Med, 382, pp.2012~2022 (2020)
- Ilie PC, "The role of vitamin D in the prevention of coronavirus disease 2019 infection and mortality", Aging Clin Exp Res, 32, pp.1195~1198 (2020)
- D’Avolio A, "25-Hydroxyvitamin D concentrations are low er in patients with positive PCR for SARS-CoV-2", Nutrients, 12, pp.1359~ (2020)
- Meltzer DO, "Association of vitamin D status and other clinical characteristics with COVID-19 test results", JAMA Netw Open, 3, pp.e2019722~ (2020)
- Radujkovic A, "Vitamin D deficiency and outcome of COVID-19 patients", Nutrients, 12, pp.2757~ (2020)
- Tehrani S, "Evaluation of vitamin D levels in COVID-19 patients referred to Labafinejad hospital in Tehran and its relationship with disease severity and mortality", Clin Nutr ESPEN, 42, pp.313~317 (2021)
- Murai IH, "Effect of a single high dose of vitamin D3 on hospital length of stay in patients with moderate to severe COVID-19 : a randomized clinical trial", JAMA, 325, pp.1053~1060 (2021)
- Marco Infante, "Low Vitamin D Status at Admission as a Risk Factor for Poor Survival in Hospitalized Patients With COVID-19: An Italian Retrospective Study", Journal of the American College of Nutrition, pp.1~16 (2021), Informa UK Limited[DOI]
- Jain A, "Analysis of vitamin D level among asymptomatic and critically ill COVID-19 patients and its correlation with inflammatory markers", Sci Rep, 10, pp.20191~ (2020)
- Pinheiro MM, "Cytokine storm modulation in COVID-19 : a proposed role for vitamin D and DPP-4 inhibitor combination therapy(VIDPP-4i)", Immunotherapy, 13, pp.753~765 (2021)
- Malek Mahdavi A, "A brief review of interplay between vitamin D and angiotensin-converting enzyme 2: Implications for a potential treatment for COVID-19", Rev Med Virol, 30, pp.e2119~ (2020)